CASTLE BIOSCIENCES INC (CSTL): Price and Financial Metrics


0.49 (-2.01%)

POWR Rating

Component Grades








Add CSTL to Watchlist
Sign Up

Industry: Medical - Services




#27 of 69

in industry

CSTL Price/Volume Stats

Current price $23.87 52-week high $26.70
Prev. close $24.36 52-week low $9.26
Day low $23.60 Volume 179,100
Day high $24.40 Avg. volume 224,551
50-day MA $21.98 Dividend yield N/A
200-day MA $18.62 Market Cap 642.37M

CSTL Stock Price Chart Interactive Chart >


  • Sentiment is the dimension where CSTL ranks best; there it ranks ahead of 78.81% of US stocks.
  • The strongest trend for CSTL is in Growth, which has been heading up over the past 26 weeks.
  • CSTL ranks lowest in Momentum; there it ranks in the 7th percentile.

CSTL Stock Summary

  • The ratio of debt to operating expenses for CASTLE BIOSCIENCES INC is higher than it is for about just 11.35% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.12 for CASTLE BIOSCIENCES INC; that's greater than it is for only 9.86% of US stocks.
  • As for revenue growth, note that CSTL's revenue has grown 55.17% over the past 12 months; that beats the revenue growth of 91.66% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to CASTLE BIOSCIENCES INC are SILK, ONTF, BMRA, JAMF, and PAVM.
  • CSTL's SEC filings can be seen here. And to visit CASTLE BIOSCIENCES INC's official web site, go to

CSTL Valuation Summary

  • In comparison to the median Healthcare stock, CSTL's price/sales ratio is 36.36% higher, now standing at 3.
  • CSTL's EV/EBIT ratio has moved up 79.2 over the prior 54 months.

Below are key valuation metrics over time for CSTL.

Stock Date P/S P/B P/E EV/EBIT
CSTL 2023-12-29 3.0 1.5 -7.7 -6.7
CSTL 2023-12-28 3.1 1.6 -8.0 -7.0
CSTL 2023-12-27 3.1 1.5 -7.9 -6.9
CSTL 2023-12-26 3.1 1.5 -7.8 -6.8
CSTL 2023-12-22 3.0 1.5 -7.7 -6.7
CSTL 2023-12-21 3.1 1.5 -7.8 -6.8

CSTL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CSTL has a Quality Grade of D, ranking ahead of 17.49% of graded US stocks.
  • CSTL's asset turnover comes in at 0.205 -- ranking 69th of 81 Healthcare stocks.
  • 500 - Internal server error

The table below shows CSTL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.205 0.848 -1.507
2021-03-31 0.211 0.848 -0.890
2020-12-31 0.258 0.845 -0.387
2020-09-30 0.386 0.857 -0.011
2020-06-30 0.451 0.868 0.367
2020-03-31 0.627 0.866 0.356

CSTL Price Target

For more insight on analysts targets of CSTL, see our CSTL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $88.50 Average Broker Recommendation 1.17 (Strong Buy)


Castle Biosciences, Inc. provides healthcare imaging services. The Company offers diagnostic and prognostic testing solutions for cancers, as well as research and development activities. Castle Biosciences serves customers in the United States.

CSTL Latest News Stream

Event/Time News Detail
Loading, please wait...

CSTL Latest Social Stream

Loading social stream, please wait...

View Full CSTL Social Stream

Latest CSTL News From Around the Web

Below are the latest news stories about CASTLE BIOSCIENCES INC that investors may wish to consider to help them evaluate CSTL as an investment opportunity.

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FRIENDSWOOD, Texas, December 20, 2023--Castle Biosciences reports inducement grants under Nasdaq Listing Rule 5635(c)(4).

Yahoo | December 20, 2023

How Much Upside is Left in Castle Biosciences, Inc. (CSTL)? Wall Street Analysts Think 67.01%

The mean of analysts' price targets for Castle Biosciences, Inc. (CSTL) points to a 67% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | December 12, 2023

Study Finds Nurse Practitioners and Physician Assistants Would Alter Patient Care Decisions Based on DecisionDx®-Melanoma Test Results

FRIENDSWOOD, Texas, December 01, 2023--Castle announced the publication of a new study that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx®-Melanoma.

Yahoo | December 1, 2023

Castle Biosciences Gains 13%, Insider Trades Reap Benefit

Last week, Castle Biosciences, Inc. ( NASDAQ:CSTL ) insiders, who had purchased shares in the previous 12 months were...

Yahoo | November 22, 2023

Castle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting

FRIENDSWOOD, Texas, November 14, 2023--Castle announced that data spanning its dermatologic portfolio of GEP tests was recently presented at the 2023 ASDS Annual Meeting.

Yahoo | November 14, 2023

Read More 'CSTL' Stories Here

CSTL Price Returns

1-mo 9.85%
3-mo 20.68%
6-mo 21.66%
1-year -2.01%
3-year -67.96%
5-year N/A
YTD 10.61%
2023 -8.33%
2022 -45.09%
2021 -36.16%
2020 95.37%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!